Overview

TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced, recurrent or metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction.

Phase:

N/A

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Capecitabine
Immune Checkpoint Inhibitors
Oxaliplatin